Status:
UNKNOWN
Umbilical Cord Blood Treatment for Refractory Immune Cytopenia
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Umbilical Cord Blood
Refractory Immune Cytopenia
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Immune-related hematocytopenia is a type of immunity Inflammatory cytopenia-mediated diseases, hormones and immunosuppressants are its first-line treatment. However, conventional immunosuppressants ar...
Detailed Description
Immune-related hematocytopenia (IRC- autoimmune hemolytic anemia (AIHA), Evans syndrome, acquired acquired pure red aplastic anemia (PRCA), autoimmune disease with cytopenia, etc.) is a type of immuni...
Eligibility Criteria
Inclusion
- Age 18-80 years (adults, elderly), gender is not limited;
- The diagnosis is definitely immune cytopenia (IRC), including autoimmune hemolytic anemia (AIHA, Hgb \<100g / L, acquired pure red aplastic anemia (PRCA, Hgb \<100g / L, EVANS syndrome ES, Hgb \<100g / L and / or platelet count \<30 × 109 / L, or cytopenia secondary to immune diseases (same treatment as before, or neutrophils \<0.5 × 109 / L), at least after hormones If the treatment is not effective (PR has not been achieved after 4 weeks of hormone therapy) or cyclosporine 3-5mg / kg / d has not reached PR for half a year.
- Those without abnormal cardiac function, abnormal liver function (total bilirubin 1.5 × ULN, ALT, AST≤3.0 × ULN), and abnormal renal function (serum creatinine≤1.0 × ULN) ④ ECOG score 0, 1 or 2; ⑤ Except autoimmunity There is no other secondary disease other than the disease; ⑥ Clearly understand the content of the trial, voluntarily participate in and complete this trial, and voluntarily sign an informed consent.
Exclusion
- Age \<18 years old or\> 80 years old;
- Patients with tumors (except carcinoma in situ); ③ Uncontrollable systemic infections or other serious diseases; ④ Women who are pregnant or lactating; ⑤ Patients with mental illness and potential impact Those with severe mental and mental illness who signed the informed consent form and followed up with the medical consultation;
Key Trial Info
Start Date :
April 20 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 20 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04420494
Start Date
April 20 2022
End Date
April 20 2022
Last Update
June 9 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730
2
Peking Union Medical College Hospital
Beijing, China, 100730